Dissolving the Truth

Investigators caught a factory analyst dissolving safety records in acid, yet the FDA secretly granted the plant permission to keep shipping critical cancer drugs to America.

[Speaker 1]: November 22nd, 2022. Investigators from the FDA walk into a manufacturing facility in Ahmedabad, India. It’s a massive plant run by a company called Intas Pharmaceuticals. And almost immediately, things feel… off. [Speaker 2]: Right. The inspectors start looking around, and in a waste bin, under a stairwell, they find a plastic bag full of torn-up documents. But it’s not just paper. The documents are wet. They’re drenched in acetic acid. [Speaker 1]: Someone was trying to dissolve the evidence. [Speaker 2]: Literally. An analyst at the factory had been caught pouring acid on official quality control records to make them illegible before the FDA could see them. And this isn’t a factory making aspirin. Intas produces critical chemotherapy drugs, injectables for cancer patients, and immunosuppressants for organ transplant recipients in the United States. [Speaker 1]: So, normally, this is an open-and-shut case. You get caught dissolving data in a trash can? You get banned. And on paper, that’s what happened. The FDA issued an "Import Alert." They put up a red light. [Speaker 2]: But here is the twist. The FDA didn’t just fail to stop those drugs. They actively issued a permission slip to let them in. [Speaker 1]: Today, we’re looking at why the FDA knew that factory was destroying evidence, yet secretly allowed fifty of its drugs to keep entering the U.S. supply chain. And it all hinges on a single legal phrase: "Confidential Commercial Information." [Speaker 2]: It’s Thursday, January 29, 2026, and you’re listening to The Angle. [Speaker 1]: Okay, so before we get into the new data released this week, we have to look at the machinery of how this actually works. Because for most of us, the supply chain is invisible. You go to CVS, you get a bottle, it has a name on it. You assume that name is the company that made the pill. [Speaker 2]: Right, and that assumption is the first mistake. Most of the time, the name on your bottle-say, McKesson or some other distributor-is just a "repackager" or a "labeler." They didn’t mix the chemicals. They didn’t press the pill. They just bought it in bulk and put their sticker on it. [Speaker 1]: And this is where the "Wall of Secrecy" comes in. The FDA knows exactly where the pill was made. They have the inspection reports. Since 2019, thanks to Katherine Eban’s reporting in *Bottle of Lies*, we’ve known that fraud is systemic in overseas manufacturing. We know inspectors find bugs in clean rooms, faked data, acid in trash cans. [Speaker 2]: But when the FDA releases those inspection reports-the Form 483s-they redact the product names. They black them out. They cite "trade secrets." So a doctor can see that a factory is failing, but they have zero way of knowing if the pill they are prescribing right now came from that specific failing factory. [Speaker 1]: Until last month. Because something shifted in December. Reporters at ProPublica-Megan Rose and Debbie Cenziper-released a tool called "Rx Inspector." And as of last week, January 23rd, they’ve dumped the full raw dataset. They didn’t get a leak. They just did the math. [Speaker 2]: It’s actually a really clever piece of reverse engineering. They took three massive, separate government databases that don’t usually talk to each other. The National Drug Code, the Facility Establishment Identifier, and something called Structured Product Labeling. [Speaker 1]: Basically triangulation. [Speaker 2]: Exactly. They built a map that connects the bottle in your cabinet directly to the inspection report the FDA tried to redact. And for the first time,…